MLYS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MLYS is a good buy right now for a beginner with a long-term horizon and $50,000-$100,000 to invest. The stock has constructive pre-market momentum near resistance, supportive analyst coverage with multiple Buy ratings, strong hedge fund accumulation, bullish options sentiment, and no recent negative news. Given the long-term thesis around lorundrostat, this looks like a favorable entry for an investor willing to hold.
Price is trading pre-market at 31.69, slightly above the pivot (28.77) and near the first resistance (31.19), with R2 at 32.68. MACD histogram is positive and expanding, which supports upward momentum. RSI_6 at 75.77 suggests the stock is running hot short term, but moving averages are converging, indicating a potential continuation phase rather than a clear breakdown. The near-term pattern data also points to a modest positive drift over the next day/week/month.
Bullish analyst coverage on lorundrostat's market opportunity, including Goldman Sachs maintaining a Buy rating and TD Cowen initiating with a Buy. BofA also raised its target to $51, indicating continued confidence in the pipeline. Hedge funds are buying aggressively, with holdings up 516.79% over the last quarter. There is no negative news in the past week, and the company’s core catalyst remains the long-term potential of lorundrostat in uncontrolled and resistant hypertension.
Goldman Sachs trimmed its target from $49 to $42, which shows some near-term moderation in upside expectations. The stock is trading close to resistance in pre-market, and RSI is elevated, so short-term upside may be less smooth from here. Insider activity is neutral, and there is no recent news flow to provide a fresh catalyst today.
No latest-quarter financial snapshot was available, so I cannot assess revenue or earnings growth from the provided data. The key fundamental story remains clinical and pipeline-driven rather than reported financial performance.
Analyst sentiment is positive overall. Goldman Sachs lowered its target to $42 from $49 but kept a Buy rating. TD Cowen initiated coverage with a Buy, citing broad blockbuster potential for lorundrostat in a $5B hypertension market. BofA raised its target to $51 from $46 and kept a Buy rating after clinical development progress. Overall, Wall Street remains constructive, with the main pro being large market potential and the main con being some recent target moderation from Goldman.
